{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-220648","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2026-05-13T12:05:18+00:00","discovered_at":"2026-05-13T12:10:00.353567+00:00","generated_at":"2026-05-13T12:17:10.690992+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spruce Biosciences Q1 net loss $12.3M; cash $54.1M (Mar 31), $107.3M (Apr 30)","bullets":["Net loss of $12.3M ($8.94 per share) for Q1 2026; R&D expenses $7.6M, G&A $4.4M.","Cash $54.1M at March 31, 2026; preliminary cash $107.3M at April 30, 2026; runway into H2 2027.","Closed $69.0M diluted public offering in April 2026; secured up to $50M term loan from Avenue Capital (Tranche 1: $15M funded).","BLA submission for TA-ERT (MPS IIIB) on track for Q4 2026; long-term data showed durable HS reduction and cognitive stabilization."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-220648","json":"https://secwatch.observer/filing/0001193125-26-220648.json","markdown":"https://secwatch.observer/filing/0001193125-26-220648.md","text":"https://secwatch.observer/filing/0001193125-26-220648.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000119312526220648/0001193125-26-220648-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000119312526220648/sprb-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T12:17:10.690992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e8d644e7c87dcc15c0aa4a7aa68f3d25c0c3c76","claim":"SPRUCE BIOSCIENCES, INC. reported preliminary financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 13, 2026, Spruce Biosciences, Inc. (the \"Company\") issued a press release announcing its financial results for the first quarter ended March 31, 2026 and providing corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000119312526220648/0001193125-26-220648-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}